MIR455

Summary

MIR455 (microRNA 455, HGNC:32344) is a microRNA gene on chromosome 9q32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 619556 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32344
Approved symbol	MIR455
Name	microRNA 455
Location	9q32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-455
Ensembl gene	ENSG00000207726
Ensembl biotype	miRNA
Entrez	619556
RNAcentral	URS000075AC6B — miRNA, 96 nt, 38 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384993

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384993 — 1 exons

Exon	Start	End
ENSE00001500000	114209434	114209529

Expression profiles

Bgee: expression breadth broad, 66 present calls, max score 83.92.

Top tissues by expression

66 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	83.92	gold quality
right coronary artery	UBERON:0001625	78.30	gold quality
fundus of stomach	UBERON:0001160	77.10	gold quality
placenta	UBERON:0001987	76.09	gold quality
calcaneal tendon	UBERON:0003701	73.44	gold quality
muscle of leg	UBERON:0001383	73.31	gold quality
right ovary	UBERON:0002118	72.55	gold quality
right lobe of thyroid gland	UBERON:0001119	72.15	gold quality
gastrocnemius	UBERON:0001388	71.96	gold quality
omental fat pad	UBERON:0010414	70.87	gold quality
body of pancreas	UBERON:0001150	70.47	gold quality
transverse colon	UBERON:0001157	70.39	gold quality
tibial artery	UBERON:0007610	70.11	gold quality
stomach	UBERON:0000945	70.02	gold quality
liver	UBERON:0002107	69.85	gold quality
ascending aorta	UBERON:0001496	69.79	gold quality
thoracic aorta	UBERON:0001515	69.65	gold quality
heart left ventricle	UBERON:0002084	69.36	gold quality
heart	UBERON:0000948	69.24	gold quality
endocervix	UBERON:0000458	69.20	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.97	gold quality
adult mammalian kidney	UBERON:0000082	68.93	gold quality
left adrenal gland	UBERON:0001234	68.73	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.73	gold quality
endometrium	UBERON:0001295	68.71	gold quality
right lobe of liver	UBERON:0001114	68.70	gold quality
colon	UBERON:0001155	68.51	gold quality
body of stomach	UBERON:0001161	68.10	gold quality
right adrenal gland	UBERON:0001233	67.96	gold quality
right atrium auricular region	UBERON:0006631	67.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.58

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• MiR-455 was underexpressed in medullary thyroid carcinoma. (PMID:23685355)
• MiR455 represses a hypoxia response that might otherwise prevent cytotrophoblasts from syncytiotrophoblast differentiation. (PMID:25188518)
• our study demonstrated that miR-455-RAF1 may represent a new potential therapeutic target for colorectal carcinoma treatment. (PMID:25355599)
• Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. (PMID:25686251)
• Data suggest that three microRNAs (miR-191-3p, miR-455-3p, and miR-1281) are up-regulated in plasma of patients with abdominal aortic aneurysms as compared to control subjects; thus, these microRNAs are potential plasma biomarkers. (PMID:25916817)
• miR-455 directly binds to 3’UTR of ZEB1 and suppresses the endogenous level of ZEB1 protein expression. overexpression of ZEB1 reverses miR-455-suppressed malignant phenotype of NSCLC cells. upregulation of ZEB1 expression is inversely associated with miR-455 expression in NSCLC tissues. Taken together, miR-455 as an anti-oncogene in non-small cell lung cancer through up-regulation of ZEB1 (PMID:26801503)
• In conclusion, we reveal that miR-455-5p expression is regulated by the TGF-beta-dependent pathway, which subsequently leads to UBE2B down-regulation and contributes to oral cancer tumourigenesis. (PMID:27235675)
• miR-455-5p was reduced significantly in gastric cancer cells and tissues . MiR-455-5p acts as a tumor suppressor in gastric cancer. (PMID:27451075)
• The miR-139-5p, 455-5p and let-7b signature, in particular, may represent an important therapeutic target in KIT/PDGFRA WT-SDH deficient GIST, usually characterized by IGF1R overexpression. (PMID:27625077)
• The findings suggest that miR-455-3p plays a critical role during chondrogenesis by directly targeting HDAC2/8 and promoting histone H3 acetylation. (PMID:27638301)
• Runx2 is a direct downstream target of miR-455 in hepatocellular carcinoma. (PMID:27748890)
• The overexpression of miR-455-3p markedly elevated the levels of Bax, pro-caspase 3, and active caspase-3, but significantly reduced the levels of Bcl-2 in HCT116 cells, demonstrating that overexpression of miR-455-3p induced cell apoptosis. Thus miR-455-3p functions as a tumor suppressor in HCT116 cells by inhibition of cell proliferation and induction of apoptosis. (PMID:27861461)
• High miR455-3p expression is associated with triple negative breast cancer. (PMID:28038450)
• miR-455 inhibits breast cancer cell proliferation through targeting CDK14 (PMID:28300591)
• Findings suggest that miR-455-3p functions as a tumor suppressor by directly targeting eIF4E in prostate carcinogenesis. (PMID:28350134)
• the present study confirmed the tumor suppressor function of miR-455 in melanoma, and demonstrated that miR-455 suppressed proliferation and invasion through directly targeting IGF-1R. (PMID:28440508)
• Low expression of miR455 is associated with gastric cancer. (PMID:28535014)
• miR-455 inhibited cell proliferation while inducing cell apoptosis by targeting HDAC2 in colorectal cancer cells. (PMID:28538837)
• MiR-455-3p promotes chemoresistance and tumorigenesis of esophageal squamous cell carcinoma. (PMID:28633632)
• these results indicate that miR455 is involved in gastric cancer progression by directly targeting IGF1R and may serve as a novel therapeutic target for the treatment of gastric cancer. (PMID:28714005)
• Overexpression of miR-455-3p enhanced the cell proliferation and invasion in esophageal squamous cell carcinoma cells, suggesting that miR-455-3p upregulation might play an important role in promoting carcinogenesis and progression of esophageal squamous cell carcinoma. (PMID:28770965)
• An increase in miR-455-3p expression found in AD patients and Abeta pathologies unveiled its biomarker characteristics and a precise role in AD pathogenesis. (PMID:28934394)
• the tumorsuppressive roles of miR455 in modulating EOC proliferation and invasion through regulation of Notch1 expression. (PMID:29039517)
• Taken together, our results for the first time suggested that miR-455-3p was downregulated in NSCLC and was correlated with the poor prognosis of NSCLC patients. Also, miR-455-3p functions as tumor suppressor by directly targeting HOXB5 in NSCLC progression and may be used as a potential target for NSCLC treatment. (PMID:29170127)
• miR4555p accelerated invasiveness and migration capabilities of breast cancer cells. (PMID:29257232)
• Exclusion of the aneurysmal sac after endovascular treatment of abdominal aortic aneurysms induces a decrease in the expression of circulating miRNA-455 levels. (PMID:29518510)
• GATA-binding protein 6 (GATA6), whose expression can be inversely regulated by miR-455 in CRC cell lines. (PMID:29615149)
• data show that miR-455-3p can regulate hMSC chondrogenic differentiation by affecting DNA methylation. Overexpression of miR-455-3p and DNA methylation inhibitors can thus potentially be utilized to optimize chondrogenic differentiation. (PMID:29748607)
• ROCK2 is a target of miR-455-3p. (PMID:29932921)
• Study demonstrated that miR-1915-3p might promote the proliferation and metastasis of breast cancer by repression of DUSP3 and serum miR-1915-3p and miR-455-3p could serve as diagnostic and predictive biomarkers for breast cancer. (PMID:30048472)
• the TGF-b/SMAD signaling pathway inhibits the ICMT-induced degeneration of endplate chondrocytes by regulating the miR-455-5p/RUNX2 axis (PMID:30132981)
• These results implicate miR-455 regulated hydrogen sulfide protection of lung epithelial cells against hypoxia-induced apoptosis by stimulating Calr (PMID:30193773)
• miR-455-5p acts as an anti-inflammatory role in multiple sclerosis, at least partially through targeting MyD88 and REL. (PMID:30310937)
• miR-455-5p/PIR axis contributed to cancer cell aggressiveness. (PMID:30444038)
• GAS5 promotes M1 macrophage polarization by acting as a competing endogenous RNA of miR-455-5p to facilitate SOCS3 expression in childhood pneumonia. (PMID:30584669)
• OXCT1-AS1 inhibited miR-455-5p to decrease its binding to the JAK1 3’-untranslated region, which could upregulate the expression of JAK1 at the protein level, thus promoting bladder cancer proliferation and invasion (PMID:30609030)
• Study revealed that DLEU2 directly bonds to miR-455 and functioned as its endogenous sponge, which could suppress pancreatic cancer (PC) cell growth and invasion. Also, SMAD2 was a direct target of miR-455, and the restoration of SMAD2 rescued cell growth and invasion that were reduced by DLEU2 knockdown or miR-455 overexpression. Low miR-455 expression and high SMAD2 expression was correlated with poor patient survival. (PMID:30838724)
• findings illustrate a role for miR-455-3p-1 in modulating FGF7-RAS/ERK signaling and suggest that an agomir of miR-455-3p-1 could inhibit the proliferation of PASMCs and mitigate PAH in vivo. (PMID:30858037)
• Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p. (PMID:30898696)
• In specimens from skull base chordoma patients MiR-455-5p was identified as a regulator of Gal9 expression. Immunopositivity for Gal9 was associated with tumor invasion, Karnofsky performance status score, and total tumor-infiltrating lymphocytes count; downregulation of miR-455-5p was correlated with tumor invasion and poor prognosis. (PMID:31197461)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir455b	ENSDARG00000080578
danio_rerio	dre-mir-455-1	ENSDARG00000099451
mus_musculus	Mir455	ENSMUSG00000070102
rattus_norvegicus	Mir455	ENSRNOG00000036266

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.